Holen Sie sich die Stockscreener-App
1.23
3.36%
0.04
Handel nachbörslich:
1.24
0.01
+0.81%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BCLI?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.19
Offen:
$1.21
24-Stunden-Volumen:
377.71K
Relative Volume:
0.31
Marktkapitalisierung:
$9.92M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.63M
KGV:
-2.8605
EPS:
-0.43
Netto-Cashflow:
$-21.84M
1W Leistung:
+3.36%
1M Leistung:
+13.89%
6M Leistung:
-44.84%
1J Leistung:
-78.42%
1-Tages-Spanne:
$1.155
$1.24
1-Wochen-Bereich:
$1.155
$1.32
52-Wochen-Spanne:
$0.7233
$6.5985
Brainstorm Cell Therapeutics Inc Stock (BCLI) Company Profile
Firmenname
Brainstorm Cell Therapeutics Inc
Sektor
Branche
Telefon
201-488-0460
Adresse
1325 AVENUE OF AMERICAS, NEW YORK, NY
Vergleichen Sie BCLI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCLI
Brainstorm Cell Therapeutics Inc
|
1.23 | 9.92M | 0 | -16.63M | -21.84M | -0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.27 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
522.27 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.00 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
568.06 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
266.80 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Brainstorm Cell Therapeutics Inc Stock (BCLI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-02-04 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-11-17 | Herabstufung | Maxim Group | Buy → Hold |
| 2016-12-19 | Bestätigt | Maxim Group | Buy |
| 2015-12-22 | Bestätigt | Maxim Group | Buy |
Brainstorm Cell Therapeutics Inc Aktie (BCLI) Neueste Nachrichten
Autologous Cell Therapy Market Size, Global Trends And Forecast to 2033 - Straits Research
Brainstorm Cell's NurOwn Study Data Shows 90% Survival Rate In ALS Patients, Stock Up In Pre-Market - Nasdaq
Encouraging Survival Data Revealed for BrainStorm's NurOwn in ALS Study (BCLI) | BCLI Stock News - GuruFocus
BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn® - PR Newswire
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Rating Increased to Sell at Wall Street Zen - Defense World
SHAREHOLDER ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Brainstorm taps Minaris to produce NurOwn for Phase 3b trial - ALS News Today
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Brainstorm Cell Therapeutics Inc.(BCLI) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Neuromuscular Disease Therapeutics Market Growth Driven - openPR.com
5 Best Stem Cell Companies to Invest In (June 2025) - Securities.io
What is Zacks Small Cap’s Estimate for BCLI FY2025 Earnings? - Defense World
Q2 Earnings Estimate for BCLI Issued By Zacks Small Cap - Defense World
BCLI: Receives Regulatory Clearance to Initiate Phase 3b ALS Trial… - MSN
BrainStorm Cell Therapeutics and Minaris partner on manufacturing NurOwn for trial - Yahoo Finance
BrainStorm partners with Minaris for ALS therapy trial By Investing.com - Investing.com South Africa
BrainStorm partners with Minaris for ALS therapy trial - Investing.com Australia
BrainStorm Cell Therapeutics (BCLI) Partners with Minaris for Nu - GuruFocus
BrainStorm Cell Therapeutics (BCLI) Partners with Minaris for NurOwn Manufacturing | BCLI Stock News - GuruFocus
BrainStorm Accelerates NurOwn ALS Treatment Development Through Major Manufacturing Deal with Minaris - Stock Titan
INVESTOR ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 2, 2024 in Brainstorm Cell Lawsuit – BCLI - ACCESS Newswire
FDA clears Phase 3b trial of NurOwn for ALS - ALS News Today
Gene And Cell Therapies Targeting Cns Disorders Market in 2025 - openPR.com
Pre-market Movers: VIGL, CVM, KDLY, VTAK... - RTTNews
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earns Hold Rating from Analysts at StockNews.com - Defense World
Brainstorm Cell Therapeutics outlines imminent Phase 3b ALS trial launch following FDA clearance and expanded manufacturing plans - MSN
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q1 2025 Earnings Call Transcript - Insider Monkey
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
What Did We Note About Insider Trading At Brainstorm Cell Therapeutics, Inc (NASDAQ: BCLI)? - Stocksregister
FDA grants clearance to BrainStorm’s Phase IIIb trial of ALS treatment - Yahoo Finance
Brainstorm Cell Therapeutics Reports Q1 2025 Financials - TipRanks
BrainStorm advances ALS treatment with FDA trial nod By Investing.com - Investing.com South Africa
BrainStorm advances ALS treatment with FDA trial nod - Investing.com Australia
Sector Update: Health Care Stocks Advance Monday Afternoon - marketscreener.com
Top Midday Gainers - marketscreener.com
BrainStorm (BCLI) Options Delisting Announced | BCLI Stock News - GuruFocus
Brainstorm Cell Therapeutics (BCLI) Advances Phase 3b ALS Trial - GuruFocus
Earnings call transcript: BrainStorm Cell Therapeutics Q1 2025 sees stock surge after trial updates - Investing.com Nigeria
Micro Cap Bid Up Aggressively On FDA Clearance Announcement - The Globe and Mail
Transcript : Brainstorm Cell Therapeutics Inc., Q1 2025 Earnings Call, May 19, 2025 - marketscreener.com
BrainStorm (BCLI) Receives FDA Green Light for NurOwn Phase 3b A - GuruFocus
BrainStorm Cleared by FDA to Begin Phase 3b Trial of NurOwn for ALS - marketscreener.com
Breaking ALS Treatment News: FDA Gives Green Light to BrainStorm's Crucial Phase 3b NurOwn Trial - Stock Titan
SEC Form DEFA14A filed by Brainstorm Cell Therapeutics Inc. - Quantisnow
BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update - StreetInsider
BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025 - PR Newswire
BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19 - The Malaysian Reserve
SEC Form 10-Q filed by Brainstorm Cell Therapeutics Inc. - Quantisnow
Brainstorm Cell Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
BrainStorm Reschedules First Quarter 2025 Financial Results Rele - GuruFocus
BrainStorm Cell Therapeutics Moves Q1 2025 Earnings Release to Today, Full Management Team to Host May 19 Call - Stock Titan
BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19 – Company AnnouncementFT.com - Financial Times
Finanzdaten der Brainstorm Cell Therapeutics Inc-Aktie (BCLI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Brainstorm Cell Therapeutics Inc-Aktie (BCLI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lebovits Chaim | President & CEO |
Sep 30 '24 |
Buy |
0.23 |
22,000 |
5,016 |
1,186,865 |
| Dagher Ibrahim B. | Chief Medical Officer |
Jul 19 '24 |
Sale |
0.35 |
63,000 |
22,069 |
0 |
0.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):